219 related articles for article (PubMed ID: 29914087)
1. Biomarkers for Early Diagnosis and Prognosis of Malignant Pleural Mesothelioma: The Quest Goes on.
Ledda C; Senia P; Rapisarda V
Cancers (Basel); 2018 Jun; 10(6):. PubMed ID: 29914087
[TBL] [Abstract][Full Text] [Related]
2. Pleural Mesothelioma: Advances in Blood and Pleural Biomarkers.
Sorino C; Mondoni M; Marchetti G; Agati S; Inchingolo R; Mei F; Flamini S; Lococo F; Feller-Kopman D
J Clin Med; 2023 Nov; 12(22):. PubMed ID: 38002620
[TBL] [Abstract][Full Text] [Related]
3. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment.
Grigoriu BD; Scherpereel A; Devos P; Chahine B; Letourneux M; Lebailly P; Grégoire M; Porte H; Copin MC; Lassalle P
Clin Cancer Res; 2007 May; 13(10):2928-35. PubMed ID: 17504993
[TBL] [Abstract][Full Text] [Related]
4. Identification of a new potential plasmatic biomarker panel for the diagnosis of malignant pleural mesothelioma.
Ferrari L; Iodice S; Cantone L; Dallari B; Dioni L; Bordini L; Palleschi A; Mensi C; Pesatori AC
Med Lav; 2022 Dec; 113(6):e2022052. PubMed ID: 36475505
[TBL] [Abstract][Full Text] [Related]
5. [microRNAs as biological indicators of environmental and occupational exposure to asbestos].
Minoia C; Sturchio E; Porro B; Ficociello B; Zambelli A; Imbriani M
G Ital Med Lav Ergon; 2011; 33(4):420-34. PubMed ID: 22452101
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma.
Pantazopoulos I; Boura P; Xanthos T; Syrigos K
Eur Respir J; 2013 Mar; 41(3):706-15. PubMed ID: 22835614
[TBL] [Abstract][Full Text] [Related]
7. Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma.
Creaney J; Yeoman D; Demelker Y; Segal A; Musk AW; Skates SJ; Robinson BW
J Thorac Oncol; 2008 Aug; 3(8):851-7. PubMed ID: 18670302
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure.
Demir M; Kaya H; Taylan M; Ekinci A; Yılmaz S; Teke F; Sezgi C; Tanrikulu AC; Meteroglu F; Senyigit A
Lung; 2016 Jun; 194(3):409-17. PubMed ID: 27032653
[TBL] [Abstract][Full Text] [Related]
9. Biomarkers in the prevention and follow-up of workers exposed to asbestos.
Foddis R; Bonotti A; Landi S; Fallahi P; Guglielmi G; Cristaudo A
J Thorac Dis; 2018 Jan; 10(Suppl 2):S360-S368. PubMed ID: 29507806
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic and prognostic biomarkers for malignant mesothelioma: an update.
Chen Z; Gaudino G; Pass HI; Carbone M; Yang H
Transl Lung Cancer Res; 2017 Jun; 6(3):259-269. PubMed ID: 28713671
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis and prognosis-review of biomarkers for mesothelioma.
Sun HH; Vaynblat A; Pass HI
Ann Transl Med; 2017 Jun; 5(11):244. PubMed ID: 28706912
[TBL] [Abstract][Full Text] [Related]
12. Serum and pleural fluid biomarkers for mesothelioma.
Creaney J; Robinson BW
Curr Opin Pulm Med; 2009 Jul; 15(4):366-70. PubMed ID: 19417672
[TBL] [Abstract][Full Text] [Related]
13. Clinical utility of diagnostic markers for malignant pleural mesothelioma.
Grigoriu BD; Grigoriu C; Chahine B; Gey T; Scherpereel A
Monaldi Arch Chest Dis; 2009 Mar; 71(1):31-8. PubMed ID: 19522163
[TBL] [Abstract][Full Text] [Related]
14. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study.
Roe OD; Creaney J; Lundgren S; Larsson E; Sandeck H; Boffetta P; Nilsen TI; Robinson B; Kjaerheim K
Lung Cancer; 2008 Aug; 61(2):235-43. PubMed ID: 18281122
[TBL] [Abstract][Full Text] [Related]
15. Soluble markers for diagnosis of malignant pleural mesothelioma.
Cristaudo A; Bonotti A; Simonini S; Bruno R; Foddis R
Biomark Med; 2011 Apr; 5(2):261-73. PubMed ID: 21473730
[TBL] [Abstract][Full Text] [Related]
16. Validity of mesothelin in occupational medicine practice.
Smolková P; Nakládalová M; Zapletalová J; Jakubec P; Vildová H; Kolek V; Petřek M; Nakládal Z
Int J Occup Med Environ Health; 2016; 29(3):395-404. PubMed ID: 26988879
[TBL] [Abstract][Full Text] [Related]
17. Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma--which is best?
Creaney J; Yeoman D; Musk AW; de Klerk N; Skates SJ; Robinson BW
Lung Cancer; 2011 Oct; 74(1):55-60. PubMed ID: 21397972
[TBL] [Abstract][Full Text] [Related]
18. Serum mesothelin and other biomarkers: what have we learned in the last decade?
Cristaudo A; Bonotti A; Guglielmi G; Fallahi P; Foddis R
J Thorac Dis; 2018 Jan; 10(Suppl 2):S353-S359. PubMed ID: 29507805
[TBL] [Abstract][Full Text] [Related]
19. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels.
Pass HI; Lott D; Lonardo F; Harbut M; Liu Z; Tang N; Carbone M; Webb C; Wali A
N Engl J Med; 2005 Oct; 353(15):1564-73. PubMed ID: 16221779
[TBL] [Abstract][Full Text] [Related]
20. Sensitivity of urinary mesothelin in patients with malignant mesothelioma.
Creaney J; Musk AW; Robinson BW
J Thorac Oncol; 2010 Sep; 5(9):1461-6. PubMed ID: 20815094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
